Efficacy, Safety And Tolerability Of Atorvastatin In Patients With Relapsing-Remitting Multiple Sclerosis In Treatment With Interferon-Beta (arianna): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group-Study, Lyon. France
Efficacy, Safety And Tolerability Of Atorvastatin In Patients With Relapsing-Remitting Multiple Sclerosis In Treatment With Interferon-Beta (arianna): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group-Study, Lyon. France(331 views visite) Brescia Morra V, Alfano B, Lanzillo R, Quarantelli M, Comerci M, Marini S, Vacca G, Amato MP, Trojano M, Brunetti A, Pozzilli C
Proceedings Of The 23rd Ectrims Meeting Lyon France, 2012 Oct 10; AbstractBook: 477-477.
Keywords Parole chiave: Not available. Non disponibili.
Affiliations Affiliazioni: *** IBB - CNR ***
References Riferimenti: Not available. Non disponibili.
Efficacy, Safety And Tolerability Of Atorvastatin In Patients With Relapsing-Remitting Multiple Sclerosis In Treatment With Interferon-Beta (arianna): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group-Study, Lyon. France
Not available. Non disponibile.
Efficacy, Safety And Tolerability Of Atorvastatin In Patients With Relapsing-Remitting Multiple Sclerosis In Treatment With Interferon-Beta (arianna): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group-Study, Lyon. France
Efficacy, Safety And Tolerability Of Atorvastatin In Patients With Relapsing-Remitting Multiple Sclerosis In Treatment With Interferon-Beta (arianna): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group-Study, Lyon. France
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(187 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease(418 visite) Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026. Impact Factor:0.913 DettagliEsporta in BibTeXEsporta in EndNote
669 Records (490 escludendo Abstract e Conferenze). Impact factor totale: 2257.076 (1622.774 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 2380.084 (1677.737 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:14:56 331 views visite. Last view on Ultima visita in data Friday 18 December 2020, 20:32:55